Rapid developments in clinical research on the hepatitis C virus infection in the last few years have led to the development of direct-acting antivirals, such as sofosbuvir, simeprevir (both of which have been approved in the US and Europe since 2014), and daclatasvir, which was approved in Europe only in 2014. These new drugs generated a change of paradigm from interferon-based therapies, as the former require shorter treatment durations and provide high cure rates with acceptable toxicity. The 65th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, The Liver Meeting® 2014, took place in Boston, Massachusetts, on 7th-11th November. This review will summarise the highlights of this meeting within the context of pivotal clinical trials and real-life data on this rapidly evolving treatment environment, which will assist clinicians in selecting the most appropriate regimen for patients.
Please view the full content in the pdf above.